

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 June 2020 (18.06.2020)



(10) International Publication Number
WO 2020/123582 A1

(51) International Patent Classification:

A61K 31/5513 (2006.01) A61P 35/00 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2019/065600

(22) International Filing Date:

11 December 2019 (11.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/778,605 12 December 2018 (12.12.2018) US

(71) Applicant: **CHEMOCENTRYX, INC.** [US/US]; 850
Maude Avenue, Mountain View, California 94043 (US).

(72) Inventors: **GOTOH, Noriko**; c/o Kakumamachi, Kanaza-
wa City, Ishikawa 920-1192 (JP). **CAMPBELL, James J.**;
2433 Downing Avenue, San Jose, California 95128 (US).

(74) Agent: **KEZER, William B.**, et al.; Mintz Levin Cohn Fer-
ris Glovsky and Popeo PC, One Financial Center, Boston,
Massachusetts 02111 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CXCR7 INHIBITORS FOR THE TREATMENT OF CANCER




FIG. 5K

(57) Abstract: Provided herein are methods of treating cancer in an individual in need thereof, the methods comprising administering to the individual a CXCR7 inhibitor. In some embodiments, additional therapeutic agents are used. Also provided herein are methods of preventing precancerous cells expressing FRS2 β from developing into cancer, the method comprising administering to an individual having precancerous cells expressing FRS2 β a CXCR7 inhibitor. In some embodiments, additional therapeutic agents are used.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*